A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Foto: Thomas Peter/Reuters/Ritzau Scanpix

Genmab gets new MS market rival after fresh FDA approval

TG Therapeutics enters the lucrative market for multiple sclerosis treatment with newly approved drug Briumvi, now in line to compete with Genmab and Novartis’ Kesimpta and Roches Ocrevus.
  • Genmab-developed drug nears blockbuster win as Novartis sees 172% sales boost
  • Subcutaneous version of Roche's blockbuster cancer drug meets study goals

For subscribers

Henrik Juuel, CFO at Bavarian Nordic. | Foto: Bavarian Nordic / Pr

Bavarian CFO eyes breakeven chance in this year's decisive final days

Foto: Coloplast / Pr

Coloplast agrees to million-dollar settlement in the US

For subscribers

Foto: Novo Nordisk / Pr

Novo Nordisk overtakes giants in market value

Foto: Jacob Ehrbahn

Despite new diabetes treatments, Novo Nordisk predicts long-term success for insulin

"We’re building a team, we already have a well founded set-up, and we’re already testing every procedure and system, because this will be the most important milestone of the year,” says van de Winkel. | Foto: PR / Genmab

CEO Jan van de Winkel: New cancer drug is Genmab's most important milestone next year

For subscribers

  • Foto: Clodagh Kilcoyne

    US won’t back 2022 patent waivers for Covid tests and treatments

    The US joins nearly three dozen nations in seeking more time and information about a potential waiver extension.

    For subscribers

  • Foto: Yves Herman

    Companies must avoid pitfalls of new patent system, advisors warn

    From next year onwards, companies will be able to launch patent applications through a shared European court. That comes with opportunities, but there are risks as well, say lawyers and advisors.

    For subscribers

  • Britt Meelby Jensen, adm. direktør i Ambu. | Foto: Ambu/PR

    Britt Meelby Jensen: Ambu must adjust itself

    Ambu CEO Britt Meelby Jensen wants to get closer to customers and strengthen the company’s ability to shift course while in motion, she says ahead of unveiling a new strategy.

    For subscribers

  • Foto: Bavarian Nordic / PR

    Nouveau riche Bavarian Nordic to grow "slightly thin" pipeline

    The Danish biotech firm’s pipeline is ”slightly thin” when omitting Covid-19 and RSV, concedes CFO Henrik Juuel, revealing that the vaccine maker will thus from next year push new assets into the pipeline addressing infectious diseases.

    For subscribers

  • Foto: Sven Hoppe/AP/Ritzau Scanpix

    Bavarian Nordic's Q3 revenue exceeds DKK 1bn

    The Danish biotech firm’s Q3 report released Wednesday morning shows the top line surpassing DKK 1bn, however skimming thin operating earnings.

    For subscribers

  • Foto: Henrik Kastenskov

    Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play

    William Demant Invest has extended its equity position in GN Store Nord to at least 10%, and whereas the Danish investment firm’s CEO says this move is wholly in line with company strategy, several analysts question the motives behind the purchase.

    For subscribers

  • Foto: GN Hearing / PR

    GN rebrands US acquisition

    Online retailer Lively changes name as a part of integrating with GN, which purchased the US-based company in 2021.

    For subscribers

  • Foto: Rob Acket/EMA

    CHMP has approved nine medications during June

    The European authority’s expert committee has now approved a total of 47 medications during 2022.

    For subscribers

  • Foto: PR / Ambu

    Ambu recalls resuscitation product

    The Danish company is recalling a resuscitation product, reports Bloomberg News after a Danish Medicines Authority announcement.

    For subscribers

  • Sanofi pivots toward boosters after Covid vaccine delays

    Sanofi ends development of Covid Messenger-RNA vaccine.

    For subscribers

  • Foto: Dado Ruvic/REUTERS / X02714

    Sanofi's big dermatology hope fails in phase III

    One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.

    For subscribers

  • Foto: Philip Davali/Ritzau Scanpix

    Danish government wants to spend USD 160m on permanent research and development tax deduction

    In a reform proposal on Tuesday, the Danish government announced plans to make the 130 percent raised tax deduction on research and development permanent. A cap on the tax value of individual companies will still be in place, however.

    For subscribers

  • Foto: Athit Perawongmetha/Reuters/Ritzau Scanpix

    Astrazeneca and EU settle missing vaccines case

    The case of the missing delivery of Covid-19 vaccines won't make it to court as the two parties agree to settle.

    For subscribers

  • Pfizer aims for a big market with its drug abrocitinib. | Foto: ANGELA WEISS/AFP / AFP

    Pfizer goes head to head with Sanofi's multi-blockbuster with new study data

    A new phase III study conducted by Pfizer comparing its drug abrocitinib with Sanofi best-seller Dupixent favors the former's medicine.
  • Construction of the new factory in Copenhagen is a major project for AGC Biologics, both locally and for the group as a whole. Opførslen af en ny fabrik i København er et stort projekt for AGC Biologics, både lokalt og for koncernen som hele. Photo shows, from left to right, Technical Director Kasper Møller, Copenhagen Site Lead Andrea Porchia, and VP of Technical Operations Christian Christensen. | Foto: Lars Thornblad

    New factory takes AGC Danmark to another level within the corporation

    Demand for medication production is now so high that AGC Biologics' Danish unit expects to sell the output of almost full production capacity at the company's new factory within three years after commissioning, expectedly in 2023.

    For subscribers

  • Lundbeck's US Headquarters in Deerfield, near Chicago, Illinois | Foto: Lundbeck / PR

    Lundbeck introduces vaccine requirement for US staff

    The Danish pharmaceutical firm is the latest of several companies operating in the US to close its doors to unvaccinated personnel.

    For subscribers

  • Foto: Tidsvilde Stine/Ritzau Scanpix

    Novo Nordisk after US delivery issues: New obesity drug launch set for H2 next year

    It is not just in the US that significant demand for Novo Nordisk's obesity drug Wegovy is having an impact. The pharmaceutical firm now reports that new launches of the drug will not take place until during the second half of 2022.

    For subscribers

  • Foto: Kevin Grønnemann

    FDA approves Ascendis' weekly growth hormone

    A growth hormone for weekly use made by Denmark's Ascendis Pharma may now be commercialized in the US after the public authority approved the company's treatment, Skytrofa.

    For subscribers

  • Seruminstituttets chefvirolog Anders Fomsgaard siger, at man er tæt på | Foto: Tobias Nicolai/IND

    Delayed Danish state Covid vaccine to be trialled on humans in 2022

    National Danish infectious disease research organization Statens Serum Institut has found a manufacturer for its in-house Covid-19 vaccine, moving it closer to testing the candidate on human subjects following a series of delays.

    For subscribers

  • Foto: Bavarian Nordic / PR

    Bavarian Nordic initiates phase II trial for Covid-19 vaccine

    In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.

    For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Clinical Operational Associate

  • Head of Regulatory Affairs Danmark

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Head of International Sales

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Application Manager

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge